This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Robin Blaney
Robin Blaney
Brussels +32 2 549 5260 Download V-card

Robin Blaney is a partner in the firm’s Life Sciences practice.  He advises pharmaceutical, biotechnology, medical device and cosmetic manufacturers and trade associations on a wide range of regulatory, compliance, transactional and legislative matters, as well as the full range of commercial agreements that span the product life-cycle in the life sciences sector.  His expertise includes clinical trial agreements, manufacturing and supply agreements, distribution and other marketing agreements, regulatory services agreements, and tenders.  He has particular experience structuring and documenting EU pharmaceutical distribution arrangements and transitional arrangements relating to product acquisitions.  Mr. Blaney writes and speaks regularly on subjects such as medical device regulation, pharmacovigilance and clinical trials.

  • Advised Salix Pharmaceuticals in the acquisition of Oceana Therapeutics, a medical device business.
  • Provided EU and UK regulatory advice to a number of the major national and multinational pharmaceutical companies and biotechnology, diagnostic, medical device, and consumer product manufacturers.
  • Represented Intercell AG in connection with its acquisition of Cytos Biotechnology Ltd’s platform technology for monoclonal antibody discovery.
  • Participated in compliance-related investigations and initiatives in respect of alleged breaches of medicines advertising, anti-bribery, manufacturing, distribution, clinical trials, and pharmacovigilance rules.
  • Counselled clients on product classification issues, including the borderlines between medicines, medical devices, cosmetics and combination products.
  • Legal 500 UK, Product Liability (2016) 
  • Legal 500 EMEA, Healthcare and Life Sciences (2015-2016)